๋ค๋ฅด๋ฒ ํฌ์ํด ์ํ
๋ค๋ฅด๋ฒ ํฌ์ํด ์ํ๋ ํฉ์ฑ ์ง์ํ ์ ํ๊ตฌ ์์ฑ ์ด์ง์ (ESA)์ ๋๋ค. ์ฐจ์ด๋์ฆ ํ์คํฐ ๋์ ์ธํฌ์์ ์ฌ์กฐํฉ DNA ๊ธฐ์ ์ ํตํด ์์ฐ๋ 165๊ฐ์ ์๋ฏธ๋ ธ์ฐ ๋จ๋ฐฑ์ง์ ๋๋ค. **์์ ์์ **: ์ํฌ์ํด ์ํ(rHuEPO)์ ๋น๊ตํ์ฌ ๋ค๋ฅด๋ฒ ํฌ์ํด์ ๋ ๊ฐ์ ์ถ๊ฐ์ ์ธ N-๊ฒฐํฉ ํ์ํ๋ฌผ ์ฌ์ฌ์ ํฌํจํ๊ณ ์์ต๋๋ค. ์ด๋ฌํ ๊ตฌ์กฐ์ ๋ณํ์ ๋ถ์๋์ ์ฆ๊ฐ์ํค๊ณ ๋์ฌ ์์ ์ฑ๊ณผ ๋ฐ๊ฐ๊ธฐ๋ฅผ ๊ทน์ ์ผ๋ก ์ฆ๊ฐ์์ผ ํฌ์ฌ ๋น๋๋ฅผ ์ค์ผ ์ ์๊ฒ ํฉ๋๋ค(์: ์ฃผ 3ํ ๋์ ์ฃผ 1ํ). ์์ํ์์๋ ์ฃผ๋ก ๊ฐ์ ๊ณ ์์ด์ ๋ง์ฑ ์ ์ฅ ์งํ(CKD)๊ณผ ๊ด๋ จ๋ ๋น์ฌ์์ฑ ๋นํ์ ๊ด๋ฆฌํ๊ธฐ ์ํด ํ๊ฐ ์ธ(off-label)๋ก ์ฌ์ฉ๋ฉ๋๋ค. ์ด๋ก ์ ์ผ๋ก ์ถ๊ฐ์ ์ธ ํ์ํ๋ฌผ ๋ณดํธ๋ง์ด ์ํฌ์ํด ์ํ๋ณด๋ค ๋ฉด์ญ์์ฑ์ ๋ฎ์ถ์ด ์์ ์ ํ๊ตฌ ๋ฌดํ์ฑ์ฆ(PRCA)์ ์ํ์ ์ค์ผ ์ ์์ง๋ง, ์์ํ ํ์์์๋ ์์ง ์ ์ฆ๋์ง ์์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Darbepoetin alfa mimics endogenous erythropoietin by binding to the **erythropoietin receptor (EpoR)** on the surface of erythroid progenitor stem cells in the bone marrow. * Binding induces receptor dimerization โ activates the **JAK2/STAT5** intracellular signaling pathway. * This cascade โ inhibits apoptosis of progenitor cells โ stimulates their proliferation and differentiation into mature **red blood cells (RBCs)**. * The increased RBC mass subsequently raises the packed cell volume (PCV) and improves tissue oxygenation.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Anemia of chronic kidney disease ยท 0.45 micrograms/kg ยท SC/IV ยท once weekly ยท Initial human dose. Adjust using clinical judgment and careful monitoring. Alternatively, convert from epoetin alfa: Total weekly dose of epoetin in Units divided by 200 = once weekly dose in micrograms darbepoetin.
- Anemia of chronic kidney disease ยท 0.45 micrograms/kg ยท SC/IV ยท once weekly ยท Initial human dose. Adjust using clinical judgment and careful monitoring. Alternatively, convert from epoetin alfa: Total weekly dose of epoetin in Units divided by 200 = once weekly dose in micrograms darbepoetin.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Patients with documented anti-rHuEPO antibodies
- Uncontrolled hypertension
- Hypersensitivity to darbepoetin or excipients in the formulation
์ด์๋ฐ์
- Anti-rHuEPO antibody formation leading to pure red blood cell aplasia (PRCA)
- Hypertension
- Seizures
- Iron deficiency (due to rapid RBC production depleting iron stores)
์ฝ๋ฌผ ์ํธ์์ฉ
- Androgens ยท May increase the sensitivity of erythroid progenitors (interaction has been used for therapeutic effect with epoetin)
- Desmopressin ยท Can decrease bleeding times when used concurrently with erythropoietin agents
๋ชจ๋ํฐ๋ง
- PCV/Hematocrit (check before each re-dosing)
- Iron stores (supplement with iron if necessary)
- Blood pressure
๊ณผ์ฉ๋
Little information is available in veterinary species. In humans, therapeutic dosages of up to 8 micrograms/kg every week for 12 weeks have been administered. Polycythemia (excessive red blood cells) is possible with overdosage, and therapeutic phlebotomy may be required to reduce blood viscosity.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.